Neurocognitive Disorders

Postoperative delirium drug pipeline

  • ICD-11 6D70
  • MeSH D003693

1 compound from 1 company is in active clinical development for postoperative delirium.

1Compound
1Company
0Phase 3+
  • Phase 2 1

Mechanisms: Peptide (1)

Pipeline data compiled July 2026 · every fact sourced.

Upcoming readouts & recent results

  • 2026-04-01ReportedCN-105Full resultsmissedNCT03802396

    MARBLE: CN-105 was safe and feasible but did not significantly reduce postoperative delirium (19.3% vs 26.5%, OR 0.66, p=0.29) or CSF cytokines in 186 randomized older surgical patients. ↗

  • 2024-09-04ReportedCN-105Registry resultsmetNCT03802396

    MARBLE tabular results posted to ClinicalTrials.gov: median Grade II+ adverse events per patient 1 (CN-105, n=137) versus 2 (placebo, n=49), p=0.025. ↗

See the full catalyst calendar →

Compounds in development (1)

CompoundCompanyPhaseStatusMechanism
CN-105AegisCN LLCPhase 2CompletedLRP1 Agonist

Trials recruiting now

1 registered interventional postoperative delirium trial — none recruiting at present. Browse all on ClinicalTrials.gov →

Frequently asked

How many drugs are in development for postoperative delirium?
1 compound from 1 company is in active clinical development for postoperative delirium.